Portfolio Management

Innovative structures and increased supply mean managers have choice when it comes to fund finance.

In a rebounding biotech market, royalty finance can play a far more strategic role, provided it’s executed with disciplined underwriting, smart structuring and a genuine partnership with innovators, according to Ryan Murr a partner at Gibson, Dunn & Crutcher.

The consultant’s survey found the finance leaders are weak on finance basics, neglect equity performance and lack urgency on exit readiness.